{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T16:12:07Z","timestamp":1726762327644},"reference-count":26,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2021]]},"DOI":"10.3960\/jslrt.20062","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T22:07:26Z","timestamp":1616018846000},"page":"35-41","source":"Crossref","is-referenced-by-count":1,"title":["Clinical characteristics of patients with B-cell lymphoma enrolled in                    clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group                    - Lymphoma Study Group study \u2013 JCOG0108A"],"prefix":"10.3960","volume":"61","author":[{"given":"Tomohiro","family":"Kinoshita","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya                            University Graduate School of Medicine, Nagoya, Japan,"},{"name":"Department of Hematology and Cell Therapy,                            Aichi Cancer Center Hospital, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer                            Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Itoh","sequence":"additional","affiliation":[{"name":"Division of Oncology and Hematology, National                            Cancer Center Hospital East, Kashiwa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Medical Center                            for Translational and Clinical Research, Hiroshima University Hospital,                            Hiroshima, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer                            Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy,                            Aichi Cancer Center Hospital, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoko","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mie                            University Graduate School of Medicine, Tsu, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsutoshi","family":"Kurosawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital                            Organization, Hokkaido Cancer Center, Sapporo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Imaizumi","sequence":"additional","affiliation":[{"name":"Nagasaki University Hospital, Nagasaki,                            Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sapporo Hokuyu                            Hospital, Sapporo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harumi","family":"Kaba","sequence":"additional","affiliation":[{"name":"Data Management Division, Clinical Research                            Support Office, National Cancer Center, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Mukai","sequence":"additional","affiliation":[{"name":"Pathology Division, National Cancer Center                            Research Institute, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pathology and Clinical                            Laboratories, Nagoya University Hospital, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Ohshima","sequence":"additional","affiliation":[{"name":"First Department of Pathology, Kurume                            University School of Medicine, Kurume, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomitsu","family":"Hotta","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology,                            National Hospital Organization Nagoya Medical Center, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, International                            Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"Clinical Research Center, National Hospital                            Organization Nagoya Medical Center, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo,                            Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Harris                            NL,                                Jaffe                            ES,                                Diebold                            J                    <i>et al.<\/i> World Health Organization classification of neoplastic                    diseases of the hematopoietic and lymphoid tissues: report of the Clinical                    Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol.                    1999; 17: 3835-3849.","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 . The World Health                    Organization classification of malignant lymphomas in Japan: incidence of                    recently recognized entities. Pathol Int. 2000; 50: 696-702.","DOI":"10.1046\/j.1440-1827.2000.01108.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Anderson                            JR,                                Armitage                            JO,                                Weisenburger                            DD. Epidemiology                    of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by                    geographic locations. Ann Oncol. 1998; 9: 717-720.","DOI":"10.1023\/A:1008265532487"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Muto                            R,                                Miyoshi                            H,                                Sato                            K                    <i>et al.<\/i> Epidemiology and secular trends of malignant lymphoma in                    Japan: analysis of 9426 cases according to the World Health Organization                    classification. Cancer Med. 2018; 7: 5843-5858.","DOI":"10.1002\/cam4.1805"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 A clinical evaluation of the                    International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The                    Non-Hodgkin\u2019s Lymphoma Classification Project. Blood. 1997; 89:                    3909-3918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 . A predictive model for                    aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993; 329:                    987-994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Seki                            R,                                Ohshima                            K,                                Fujisaki                            T                    <i>et al.<\/i> Prognostic impact of immunohistochemical biomarkers in                    diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 2009; 100:                    1842-1847.","DOI":"10.1111\/j.1349-7006.2009.01268.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 National cancer institute sponsored study                    of classifications of non-hodgkin\u2019s lymphomas. Summary and description of a                    working formulation for clinical usage. Cancer. 1982; 49:                    2112-2135.","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"9","unstructured":"9 Jaffe ES, Harris NL, Stein H, Vardiman JW,                    eds. World Health Organization Classification of Tumors. Pathology and Genetics                    of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press.                    2001."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Itoh                            K,                                Kinoshita                            T,                                Watanabe                            T                    <i>et al.<\/i> Prognostic analysis and a new risk model for Hodgkin                    lymphoma in Japan. Int J Hematol. 2010; 91: 446-455.","DOI":"10.1007\/s12185-010-0533-9"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Watanabe                            T,                                Kinoshita                            T,                                Itoh                            K                    <i>et al.<\/i> Pretreatment total serum protein is a significant                    prognostic factor for the outcome of patients with peripheral T\/natural                    killer-cell lymphomas. Leuk Lymphoma. 2010; 51: 813-821.","DOI":"10.3109\/10428191003721359"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Kinoshita                            T,                                Hotta                            T,                                Tobinai                            K                    <i>et al.<\/i> A randomized controlled trial investigating the survival                    benefit of dose-intensified multidrug combination chemotherapy (LSG9) for                    intermediate- or high-grade non-Hodgkin\u2019s lymphoma: Japan Clinical Oncology                    Group Study 9002. Int J Hematol. 2004; 80: 341-350.","DOI":"10.1532\/IJH97.04085"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Mizoroki                            F,                                Hirose                            Y,                                Sano                            M                    <i>et al.<\/i> A phase II study of VEPA\/FEPP chemotherapy for                    aggressive lymphoma in elderly patients: Japan Clinical Oncology Group Study                    JCOG9203. Int J Hematol. 2006; 83: 55-62.","DOI":"10.1532\/IJH97.05084"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Itoh                            K,                                Ohtsu                            T,                                Fukuda                            H                    <i>et al.<\/i> Randomized phase II study of biweekly CHOP and                    dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in                    aggressive non-Hodgkin\u2019s lymphoma: Japan Clinical Oncology Group Study 9505. Ann                    Oncol. 2002; 13: 1347-1355.","DOI":"10.1093\/annonc\/mdf287"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Tobinai                            K,                                Hotta                            T. Clinical                    trials for malignant lymphoma in Japan. Jpn J Clin Oncol. 2004; 34:                    369-378.","DOI":"10.1093\/jjco\/hyh060"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Kagami                            Y,                                Itoh                            K,                                Tobinai                            K                    <i>et al.<\/i> Phase II study of cyclophosphamide, doxorubicin,                    vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low-                    and low\u2013intermediate risk, aggressive non-Hodgkin\u2019s lymphoma: final results of                    the Japan Clinical Oncology Group Study, JCOG9508. Int J Hematol. 2012; 96:                    74-83.","DOI":"10.1007\/s12185-012-1101-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Ohmachi                            K,                                Tobinai                            K,                                Kobayashi                            Y                    <i>et al.<\/i> Phase III trial of CHOP-21 versus CHOP-14 for aggressive                    non-Hodgkin\u2019s lymphoma: final results of the Japan Clinical Oncology Group                    Study, JCOG 9809. Ann Oncol. 2011; 22: 1382-1391.","DOI":"10.1093\/annonc\/mdq619"},{"key":"18","unstructured":"18 World Health Organization. WHO Handbook for                    Reporting Results of Cancer Treatment. Geneva, WHO Offset Publication No. 48.                    1979."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Wilder                            RB,                                Rodriguez                            MA,                                Medeiros                            LJ                    <i>et al.<\/i> International prognostic index-based outcomes for                    diffuse large B-cell lymphomas. Cancer. 2002; 94: 3083-3088.","DOI":"10.1002\/cncr.10583"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Rosenwald                            A,                                Wright                            G,                                Chan                            WC                    <i>et al.<\/i> The use of molecular profiling to predict survival after                    chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346:                    1937-1947.","DOI":"10.1056\/NEJMoa012914"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Hans                            CP,                                Weisenburger                            DD,                                Greiner                            TC                    <i>et al.<\/i> Confirmation of the molecular classification of diffuse                    large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood.                    2004; 103: 275-282.","DOI":"10.1182\/blood-2003-05-1545"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Hiddemann                            W,                                Cheson                            BD. How we                    manage follicular lymphoma. Leukemia. 2014; 28: 1388-1395.","DOI":"10.1038\/leu.2014.91"},{"key":"23","unstructured":"23 Swerdlow SH, Campo E, Harris NL, et al.,                    eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th                    ed, Lyon, IARC. 2017."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Schmidt                            C,                                Dreyling                            M. Therapy of                    mantle cell lymphoma: current standards and future strategies. Hematol Oncol                    Clin North Am. 2008; 22: 953-963.","DOI":"10.1016\/j.hoc.2008.07.001"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Fisher                            RI,                                Dahlberg                            S,                                Nathwani                            BN                    <i>et al.<\/i> A clinical analysis of two indolent lymphoma entities:                    mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated                    lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group                    study. Blood. 1995; 85: 1075-1082.","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Thieblemont                            C,                                Berger                            F,                                Dumontet                            C                    <i>et al.<\/i> Mucosa-associated lymphoid tissue lymphoma is a                    disseminated disease in one third of 158 patients analyzed. Blood. 2000; 95:                    802-806.","DOI":"10.1182\/blood.V95.3.802.003k19_802_806"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/1\/61_20062\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T04:34:53Z","timestamp":1616214893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/1\/61_20062\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.20062","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}